Abstract: Provided is an agent for improving mitochondrial function including a hydroxycitric acid derivative represented by the following Formula (I) or a salt thereof, as an active ingredient [(In Formula (I), R1 and R2 each independently represent a hydrogen atom or any one group selected from the group represented by the following Formula (Ia) (here, R1 and R2 do not represent hydrogen atoms at the same time), X1 to X3 each independently represent a nitrogen or an oxygen atom, and R3, R4, R5, R3? R4?, and R5? each independently represent a hydrogen atom, or a chained hydrocarbon group (here, in a case where X1, X2, and X3 each independently represent an oxygen atom, corresponding R3?, R4?, or R5? does not exist). In Formula (Ia), R6 to R8 each independently represent a hydrogen atom, an aryl group, or a chained hydrocarbon group having 1 to 30 carbon atoms].

Abstract: The present invention provides a skin barrier function-improving agent including an inositol derivative as an active ingredient in which inositol and saccharide are bonded, and a composition for improving a skin barrier function including the above skin barrier function-improving agent and a pharmacologically acceptable carrier.

Abstract: The present invention provides a moisturizing agent including an inositol derivative as an active ingredient in which saccharide of three or more monosaccharide unit is bonded to per molecule of inositol.

Abstract: A tocopherol phosphoric acid ester represented by a following formula (1) (in the formula, R1, R2, and R3 each independently represents a hydrogen atom or a methyl group,), a pharmacologically-acceptable salt thereof, or a solvate thereof for use in the improvement of skin color.

Abstract: A method for adjusting calcium ion in epidermis is described. The method involves applying a material for enhancing skin barrier function to the skin of a subject.

Abstract: A method for adjusting calcium ion in epidermis is described. The method involves applying a material for enhancing skin barrier function to the skin of a subject.

Abstract: The present invention relates to a dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1): and/or a salt thereof, wherein R1, R2, R3, R4, R5, and R6 each independently represent a hydrogen atom or a C1-4 alkyl group, and a skin preparation for external use comprising the dendrite elongation inhibitor for melanocytes as an active ingredient.

Abstract: A method for developing an excellent material for enhancing skin barrier function, and providing a cosmetic which is developed based on the method and has excellent ability to enhance skin barrier function is described. The method evaluates skin barrier function by the steps of 1) culturing normal human epidermal cells in wells having a semipermeable membrane with two sides, in presence and absence of a test substance; 2) adding a medium not containing metal ions to a first side of the semipermeable membrane in each well and a medium containing the metal ions to a second side of the semipermeable membrane in each well, provided that the cells are adhered to the first side of the semipermeable membrane; 3) culturing the cells; 4) measuring the concentration of the metal ions in each medium; and 5) calculating permeability of the metal ions in the epidermal cell layer based on the measured concentrations of the metal ions in each media.

Abstract: The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic ? cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and a substance which inhibits the expression or enzymatic activity of a protein capable of a condensed purine derivative, which comprises using the condensed purine derivative and a pancreatic ? cell or a treated product of the cell or a protein capable of binding to the condensed purine derivative.

Abstract: The present invention relates to a dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1): and/or a salt thereof, wherein R1, R2, and R3 each independently represent a C1-4 alkyl group or hydrogen atom, and a skin preparation for external use comprising the dendrite elongation inhibitor for melanocytes as an active ingredient.

Abstract: The present invention relates to a dendrite elongation inhibitor for melanocytes consisting of a compound represented by the following general formula (1): and/or a salt thereof, wherein R1, R2, and R3 each independently represent a C1-4 alkyl group or hydrogen atom, and a skin preparation for external use comprising the dendrite elongation inhibitor for melanocytes as an active ingredient.

Abstract: A control portion A transmits only a transmission right to a control portion B. The control portion B receives the transmission right sent from the control portion A, obtains transmission-requested data B from a utilization portion B, and then transmits it with the transmission right to the control portion A. The control portion A receives the data B and transmission right transmitted from the control portion B. If the control portion A is receiving a transmission request for data A from the utilization portion A at this time, it first obtains the transmission-requested data A from the utilization portion A and transmits it to the control portion B together with the transmission right. After transmitting the data A, the control portion A transfers the data B received from the control portion B to the utilization portion A.

Abstract: A method of making a schedule that enables a user to visit a plurality of places such as entertainment spots and sightseeing spots in optimal order based on waiting time at those places, and a schedule distribution system using the method are provided. At each of those places, an information provider apparatus 30 for detecting waiting time is placed in advance. A server 20 collects waiting time at each information provider apparatus 30 at any time. Upon receipt of a schedule distribution request from a mobile communications terminal 10, the server 20 first obtains a current position of the mobile communications terminal 10. The server 20 then calculates traveling time from the current position of the mobile communications terminal 10 to each place (that is, each information provider apparatus 30). The server then adds the waiting time and the traveling time together for each information provider apparatus 30 to calculate time require for entering the place (information provider apparatus 30).

Abstract: In radio communication, the invention delivers a transmission signal wave from a transmission station to a plurality of receiving stations whereby the signal wave places the station in communication with the receiving stations using the same carrier passage reciprocally. The transmission station can determine the service condition of the carrier passage on the space in which communication takes place so that generation of the carrier wave which interferes with the station in the midst of communication can be prevented. There is a signal wave transmitter for transmitting specified signal waves from the other station at intervals shorter than the transmission intervals of the response signals. There is a monitor for monitoring whether the interference wave exists in the carrier passage on the space in which the delivery of the waves is about to be performed when an optional station of the radio communication stations begins to deliver the transmission wave or transmit the signal wave.